🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

25 recruiting trials

for BRAF V600E Mutation

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer NCT06008119Phase 31 site📍 Beijing Shanghai Kechow Pharma, Inc. · Tests: Tunlametinib plus Vemurafenib, Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System NCT07870265NA1 site📍 Brno Masaryk Memorial Cancer Institute · Tests: Novel CRISPR/Cas12a Electrochemical Bioassay, Reference Standard Molecular Diagnostics (NGS and ddPCR), Serial Peripher… Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer NCT06603376Phase 21 site📍 Shanghai Shanghai Changzheng Hospital · Tests: FOLFIRI + Vemurafenib + Cetuximab, FOLFIRI ± Bevacizumab A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer NCT07506109Phase 24 sites📍 Beijing📍 Wuhan📍 Chengdu Tianjin Medical University Cancer Institute and Hospital · Tests: Ipilimumab N01, Sintilimab, Cetuximab, Dabrafenib Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors NCT05868629n/a8 sites📍 Torrance📍 Denver📍 Washington D.C. Novartis Pharmaceuticals · Tests: Non-investigational Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy NCT03042221n/a1 site📍 Aurora University of Colorado, Denver XL092 and Cemiplimab in BRAF WT Thyroid Cancer NCT06902376Phase 12 sites📍 Boston📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: Cemiplimab, XL092 Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma NCT06653517Phase 21 site📍 Shanghai Shanghai Ninth People's Hospital Affiliated to Shanghai Jia… · Tests: Dabrafenib, Trametinib Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer NCT05706779Phase 21 site📍 Paris Federation Francophone de Cancerologie Digestive · Tests: Encorafenib Oral Capsule + Cetuximab Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies NCT05786924Phase 1, Phase 249 sites📍 Gilbert📍 Los Angeles📍 Los Angeles Institut de Recherches Internationales Servier · Tests: S241656, FOLFOX6/FOLFOX7, FOLFIRI, Cetuximab, Panitumumab A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mutant Colorectal Cancer With or Without Resectable Metastases NCT07789210Phase 21 site📍 Hangzhou Zhejiang University · Tests: Neoadjuvant therapy of encorafenib plus cetuximab N01 and mFOLFOX6 Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer NCT06207656Phase 21 site📍 Madrid Spanish Cooperative Group for the Treatment of Digestive Tu… · Tests: EBC A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer NCT05639413NA45 sites📍 Avignon📍 Bayeux📍 Beauvais UNICANCER · Tests: Collection of blood samples Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer NCT06102902Phase 116 sites📍 Costa Mesa📍 Irvine📍 Los Angeles National Cancer Institute (NCI) · Tests: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Cetuximab, Computed Tomography Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. NCT06640166Phase 23 sites📍 Milan📍 Roma📍 Tricase Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Tests: encorafenib + cetuximab + FOLFIRI Combination Therapy for BRAF-V600E Metastatic CRCm NCT06411600Phase 21 site📍 Barcelona Vall d'Hebron Institute of Oncology · Tests: Encorafenib, Cetuximab, Bevacizumab A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma NCT06610682EARLY Phase 12 sites📍 Baltimore📍 New York Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: Plixorafenib, Retifanlimab Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients NCT07809893Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Ivonescimab +mFOLFOXIRI +celecoxib A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations NCT05503797Phase 270 sites📍 Beverly Hills📍 San Francisco📍 Westwood, Los Angeles Fore Biotherapeutics · Tests: Plixorafenib Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer NCT07617610n/a13 sites📍 Aarau📍 Baden📍 Basel Swiss Cancer Institute · Tests: Longitudinal translational sampling Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer NCT06763029Phase 21 site📍 Shanghai Fudan University · Tests: Irinotecan liposomes combined with cetuximab + vermofenib Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer NCT07150247Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Iparomlimab and Tuvonralimab, Bevacizumab, 5-Fluorouracil, Irinotecan (drug) Special Drug Use-results Surveillance of Tafinlar/Mekinist NCT06262919n/a70 sites📍 Nagakute📍 Nagoya📍 Nagoya Novartis Pharmaceuticals · Tests: Tafinlar/Mekinist A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer NCT06978400Phase 21 site📍 Moscow Blokhin's Russian Cancer Research Center · Tests: mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases NCT06887088Phase 218 sites📍 A Coruña📍 Barcelona📍 Barcelona Grupo Español Multidisciplinar de Melanoma · Tests: Encorafenib + Binimetinib, cemiplimab+fianlimab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy